Drug intelligence / Profile preview

curepeptin

Development stage: Preclinical
Lead developer: FunPep
Modality: Peptides, Small Molecules

Overview

Curepeptin is a chemically synthesized antimicrobial peptide composed of natural amino acids. It exerts its effect by disrupting bacterial cell membranes, leading to broad-spectrum antimicrobial activity. Notably, Curepeptin has demonstrated effectiveness against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Acinetobacter, and NDM-1-producing bacteria. The drug is being developed as a novel therapeutic option for infections caused by resistant pathogens[1].

Brand names: Curepeptin
Other names: Curepeptin

Beyond the preview

Go deeper on curepeptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on curepeptin.

Explore the full profile